Newish Biotech starts randomized trial testing if NWRD09 clears persistent HPV16
The Chinese biotech's third NWRD09 trial targets viral clearance rather than lesion regression, testing an earlier stage of HPV16 disease than its other studies.
Executive Summary
- Newish Biotech (Wuxi) Co., Ltd. opened a randomized, quadruple-masked trial of NWRD09 in women with persistent cervical HPV16 infection, an interventional study with no phase classification typical of a biologic aimed at clearing viral infection before it becomes precancerous.
- The trial sits alongside two other active NWRD09 studies from the same sponsor family, moving the asset earlier in the disease course, from established lesions and cancer toward infection that has not yet progressed.
- The persistent-HPV16 field carries few programs testing viral clearance as a primary endpoint, and no approved therapy for this indication appears on record, leaving the trial's own primary result as the first test of whether NWRD09 can achieve clearance at this stage.
- The primary completion date falls in November 2026, when the trial will report the proportion of participants with confirmed HPV16 clearance at week 16, the first readable signal from this earlier-stage strategy.
The new trial
Newish Biotech (Wuxi) Co., Ltd. registered NCT07710703, a randomized, quadruple-masked, two-arm interventional trial testing NWRD09 in women 45 to 65 with HPV16 infection confirmed positive for at least 12 months before screening. The trial targets 60 participants and started enrolling on February 10, 2026, running at sites in China. NWRD09 is given intramuscularly, and the trial excludes women with any confirmed cervical adenocarcinoma, high-grade intraepithelial neoplasia, or invasive cancer, restricting the population to infection that has not yet progressed to serious lesions. NCT07710703NWRD09 for Persistent Cervical HPV16 InfectionNCT07710703
The endpoint
The primary endpoint measures the proportion of participants with virologically confirmed clearance of HPV16 at week 16, with a primary completion date of November 30, 2026. Secondary measures track adverse events through 36 weeks, cellular immune responses by ELISPOT assay at baseline and weeks 6, 16 and 28, and histopathological regression of any baseline low-grade lesions by week 28. That endpoint structure, viral clearance first, lesion regression second, distinguishes a trial designed to catch and resolve infection before disease develops, rather than to treat lesions or cancer already present. NCT07710703NWRD09 for Persistent Cervical HPV16 InfectionNCT07710703
Pipeline positioning
Newish Biotech runs a six-trial pipeline, four recruiting and two not yet recruiting. Two other NWRD09 trials are active: a Phase 1 study in general HPV16 infection and a Phase 2 study, both from related Newish entities, alongside separate studies in HPV16-related intraepithelial neoplasia and cervical cancer. This trial sits at the earliest point in that disease progression the program has tested, using persistent infection rather than an established lesion as its entry criterion, and applies a randomized, masked design where the sponsor's other early-stage NWRD09 studies do not carry the same allocation and masking structure. NWRD09NWRD09 for Persistent Cervical HPV16 InfectionJul 17, 2026
The competitive field
The broader HPV16 field surfaced in this search includes PDS Biotechnology's PDS0101 in combination with pembrolizumab for head and neck cancer and TScan Therapeutics' TCR-T cell therapy in a tumor-agnostic basket trial, both testing mechanisms distinct from viral clearance in earlier-stage infection. Neither is a direct comparator on target, modality, or disease stage.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.